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a b s t r a c t
Sarcomas are rare and clinically diverse malignancies, and treatment optimization requires
the development of suitable biomarkers. In earlier research employing proteomics anal-
ysis, we identiﬁed peroxiredoxin 2 as a biomarker of osteosarcoma (OS) that can predict
response to neoadjuvant chemotherapy and veriﬁed its functional signiﬁcance in the resis-
tance of OS cells to chemotherapeutic drugs. In addition, in gastrointestinal stromal tumor
(GIST), we identiﬁed pfetin as a prognostic biomarker and validated its prognostic utility inastrointestinal stromal tumor
eroxiredoxin 2
fetin
wo-dimensional difference gel
multi-institutional studies by immunohistochemistry. Here, we present an overview of our
progress in sarcoma proteomics and discuss future perspectives.
© 2014 Published by Elsevier B.V. on behalf of European Proteomics Association (EuPA).
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
[7,8], protein localization [9,10], and protein function [11,12].lectrophoresis
. Clinical features of sarcomas and the
eed for biomarker development
arcomas are rare and highly diverse mesenchymal malig-
ancies, arising from bone, cartilage, muscle, fat, peripheral
erves, and adipose or ﬁbrous connective tissues [1]. Sarcomas
ffect ∼200,000 individuals worldwide each year, accounting
or less than 1% of all adult malignant tumors. Sarcomas
re classiﬁed into more than 50 histological subtypes, many
f which have unique clinical, prognostic, and therapeu-
ic features. Clinically, sarcomas range from curable tumors
o those causing aggressive, incurable disease. Standard
hemotherapy protocols have been established for only few
arcoma types; for others, numerous molecular-targeting
reatments are currently under investigation [2]. In order to
ptimize the response of sarcomas to therapeutic interven-
ion and minimize any treatment-related toxicity that could
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212-9685/© 2014 Published by Elsevier B.V. on behalf of European Prote
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3compromise clinical efﬁcacy, novel biomarkers are urgently
required.
2. Proteomics approach toward
characterization of biomarkers using tumor
tissues
The proteome is a functional representation of the genome
that directly characterizes cell or organism phenotypes. Pro-
teomics can provide unique proteome data on the level of
protein expression [3,4]; status of protein complexes [5,6]; and
post-translational modiﬁcations such as phosphorylation,
ubiquitination, glycosylation, acetylation, and ribosylationCancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo
cc.go.jp (T. Kondo).
By integrating these data with clinical observations, it may
be possible to identify biomarkers that could be useful for
evaluating the malignant potential of different sarcomas.
omics Association (EuPA). This is an open access article under the
.0/).
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For studying the sarcoma proteome, we had employed
two-dimensional difference gel electrophoresis (2D-DIGE)
[13], where protein samples labeled with different spec-
trally resolvable ﬂuorescent dyes are separated by 2D gel
electrophoresis (2D-GE). The gels are then laser-scanned
using dye-speciﬁc excitation wavelength enabling to see
each sample separately. In general, 2D-DIGE allows more
comprehensive protein expression proﬁling than classical 2D-
GE, which is especially important for the studies of cancer
biomarkers [14–16]. First, gel-to-gel variations can be com-
pensated for by using a common internal pooled control (a
mixture of individual samples labeled with a ﬂuorescent dye
different from that of individual samples) allowing quanti-
tative comparison of multiple specimens. Second, 2D-DIGE
provides parallel assessment of several experiments, which
is essential for biomarker studies based on repeated exam-
ination of many samples within a relatively short period of
time. In 2D-DIGE, it can be achieved by simultaneous use of
electrophoretic instrumentation, since the cost of performing
electrophoresis is relatively low. Moreover, protein detection
is performed using laser scanning, allowing high-throughput
analysis of multiple samples. Third, contrary to conventional
2D-GE, in 2D-DIGE large-format gels displaying thousands of
protein spots can be used [17,18] because, contrary to col-
orimetric staining, the detection by laser scanning does not
require handling of fragile, easily breakable polyacrylamide
gels. In our experiments, up to 5000 protein spots could be
observed in a single gel during 2D-DIGE [16]. Finally, 2D-DIGE
offershigh sensitivity of proteindetection [19],which is critical
for biomarker studies based on size-limited clinical speci-
mens. We have reported that very small samples (micrograms
of protein), such as those obtained by laser microdissection,
can generate thousands of protein spots after labeling with a
highly sensitive ﬂuorescent dye [19] (a detailed protocol pub-
lished in [16]). Thus, the major advantages of 2D-DIGE as a
modality for proteomic biomarker studies are comprehen-
sive high throughput analysis, high sensitivity, and reduction
of inter-gel variability, which provides quantitative compari-
son of biological changes and reduces experimental bias. The
combination of these factors makes 2D-DIGE a more reliable
approach to the identiﬁcation of clinically relevant cancer
biomarkers for prediction of treatment response compared
to other proteomic techniques, which may be superior in
terms of individual parameters. That is why 2D-DIGE has been
widely used in biomarker studies resulting in identiﬁcation of
a number of proteins that correlate with clinical parameters
in various cancers.
3. General strategy for biomarker
development
In 2002, Anderson et al. published a landmark paper where
they evaluated proteins according to the expected expression
levels in plasma [20]. At that time, conventional proteomics
made limited contribution to the list of plasma biomarkers
used in the hospitals. Since then, the advances in pro-
teomic technology resulted in considerable improvement of
the sensitivity in protein detection, holding promise that
comprehensive proteomics might instantly lead to successful4 ( 2 0 1 4 ) 121–128
biomarker identiﬁcation. However, global expression proﬁling
alone may not necessarily be so successful. Thus, transcrip-
tomics, which quantitatively monitors mRNA synthesis using
DNA microarray technology, has been extensively used in
biomarker studies over the last decade [21–23]. However,
among hundreds of reported mRNA candidate biomarkers,
only few advanced to clinical application [24,25], suggesting
that although comprehensive technology is potentially bene-
ﬁcial for biomarker discovery, it may not warrant successful
identiﬁcation of clinically relevant molecules.
Biomarker studies should be based on profound under-
standing of disease background and conducted to meet
clinical demands [26,27]. Based on speciﬁc clinical require-
ments, samples should be appropriately stratiﬁed according
to clinical characteristics, and informative proteins can be
revealed through comparative studies. However, researchers
conducting basic proteomic studies generally do not have
medical backgroundor access to clinical data. Therefore, inter-
disciplinary collaboration betweenbasic and clinical scientists
is mandatory in biomarker studies.
On the basis of this concept, in 2004, we launched a col-
laborative project on sarcoma proteomics that united efforts
of basic and clinical researches. Six young medical doctors
specializing in sarcoma have participated in our sarcoma
proteomics project. In Japan, basic laboratory experience
is a mandatory part of medical training, and employing a
problem-oriented research style,wehave incorporated clinical
approach into our proteomics project.
The biobanking system at the National Cancer Center in
Tokyo provides an invaluable source of clinical samples for
research purposes. Tumor tissues (frozen in vapor nitrogen)
from over 1000 sarcoma patients are stored anonymously but
could still be traced by medical records such as pathologi-
cal diagnosis, treatment, and clinical outcome. These samples
have been the basis of our sarcoma proteomics project.
In addition to the proteome, we also used the data on the
sarcoma transcriptome and genome and found that most of
this information does not overlap and that integration of these
data is quite challenging. These issues will be discussed else-
where.
4. Approach to study sarcoma proteome
When we began sarcoma proteomic studies in 2004, there
had been no established approaches to proteomics in can-
cer research, especially with regard to sarcoma. When we
employed 2D-DIGE to generate global protein expression
proﬁles of 80 soft-tissue sarcoma samples with seven dif-
ferent histological backgrounds, we found that histologically
identical sarcomas shared common proteomic features [28],
consistentwith the results of a previousDNAmicroarray study
showing a similar tendency for the sarcoma transcriptome
[29].
Sarcomas exhibit a clinically wide spectrum from curative
to malignant disease, the latter being associated with metas-
tasis and treatment resistance. These clinical characteristics
often correspond to histological subclasses and grading [30].
Accordingly, our preliminary observations encouraged further
proteomic studies as part of general efforts in the discovery
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f sarcoma biomarkers. We examined various sarcoma types,
ncluding osteosarcoma [31,32], Ewing’s sarcoma [33–35],
astrointestinal stromal tumor [36–44], synovial sarcoma
45,46], myxoid liposarcoma, myxoﬁbrosarcoma, leiomyosar-
oma, alveolar soft tissue sarcoma [47], rhabdomyosarcoma,
pitheloid sarcoma, and giant cell tumor. Here, we describe
steosarcoma (OS) and gastrointestinal stromal tumor (GIST)
s examples of our sarcoma biomarker studies.
. Osteosarcoma
steosarcoma (OS) is the most common type of primary
one cancer, which accounts for 35% of all primary bone
alignancies [48] and frequently affects children and ado-
escents [49]. In Japan, approximately 200 patients develop
S annually. High-dose multi-agent neoadjuvant chemother-
py regimens have improved the cure rate of localized OS
o approximately 80%, as compared with 15–20% achieved by
urgery alone [50,51]. Neoadjuvant pre-operative chemother-
py targets micrometastasis and reduces tumor vascularity
nd growth [52], thus allowing complete eradication of all
umor cells after the surgery. In OS, the response to neoad-
uvant treatment is evaluated in terms of post-treatment
umor necrosis; according to the HUVOS grading system,
atients showing <90% necrosis are classiﬁed as poor respon-
ers [49]. Currently, OS response to induction chemotherapy
ollowing deﬁnitive surgery is the most reliable predictor of
ong-term outcome and is used to guide the choice of adjuvant
hemotherapy [53–59]. In order to optimize therapeutic strate-
ies and discover novel therapeutic targets, it is imperative to
dentify the molecular background of poor responders. Given
hat OS is a form of sarcomawith complex genetics [30], global
xpression studies may be effective for the identiﬁcation of
he proteins associated with clinical parameters. Thus, global
ranscriptome studies have identiﬁed several intriguing pre-
ictive biomarker candidates [60,61]; however, until recently
heir clinical utility has not been conﬁrmed. In our proteomic
tudies, we attempted to clarify the molecular nature of OS
esistance to neoadjuvant chemotherapy.
To develop biomarkers for the prediction of OS response
o neoadjuvant treatment, we performed proteomics analysis
f open (surgical) biopsy samples obtained from OS patients
rior to induction chemotherapy. After pathologic diagnosis of
S, 12 patients received combinationneoadjuvant chemother-
py with ifosfamide, doxorubicin, and cisplatin [31], and 13
ere treated with methotrexate, doxorubicin, and cisplatin
32]. Patients were stratiﬁed for adjuvant therapy on the basis
f their therapeutic response according to the HUVOS grad-
ng system at the time of surgery [49], and protein proﬁles
f patients responsive and non-responsive to neoadjuvant
reatment were compared using 2D-DIGE. Other than the
esponse to treatment, no statistically signiﬁcant difference
n clinical parameters was observed. In the patients treated
ith ifosfamide, doxorubicin, and cisplatin, we identiﬁed
5 protein spots containing 38 unique proteins as predic-
ive candidate biomarkers [31]. In the patients treated with
ethotrexate, doxorubicin, and cisplatin, 33 protein spots
ontaining 27 unique proteins were determined as potential
redictive biomarkers [32]. Further investigation revealed that( 2 0 1 4 ) 121–128 123
the expression of peroxiredoxin 2 (PRDX2) was signiﬁcantly
upregulated in the patients with poor response to both types
of combination neoadjuvant chemotherapy [31,32].
PRDX2 belongs to the peroxiredoxin family of antioxi-
dant enzymes, important for hydroperoxide detoxiﬁcation
andhighly reactivewith hydrogen peroxide, organic hydroper-
oxides, and peroxynitrite [62]. PRDX2 scavenges free radicals,
and is suggested to protect tumor cells from environmental
stress such as chemotherapy drugs and to promote tumor
formation. Thus, PRDX2 has been associated with the malig-
nant potential of breast cancer [63], colorectal cancer [64,65],
prostate cancer [66], and melanoma [67]; however, until our
studies, its role in OS development was unclear. PRDX2 is
known to promote proliferation [64], metastasis [67], stress
response [63,65], resistance to therapy [68], and signal trans-
duction [64,66] in tumor cells, and is considered to be a
potential drug target for anticancer therapy [69,70]. Using
western blotting, we conﬁrmed that overexpression of PRDX2
was associated with the resistance of OS patients to neoad-
juvant chemotherapy. Among the patients who received
ifosfamide, doxorubicin, and cisplatin, independent cases
were examined, and the predictive value of PRDX2 was suc-
cessfully validated [31]. In a prospective study, we found that
one patient who had a PRDX2-positive primary tumor showed
poor response to treatment with ifosfamide, doxorubicin, and
cisplatin. We also conﬁrmed PRDX2 localization in OS cells
by immunohistochemistry [32]. Using gene silencing assays,
we functionally veriﬁed PRDX2 contribution to both resistance
to individual chemotherapeutic drugs such as methotrexate,
doxorubicin, and cisplatin, and malignant potential in three
OS cell lines. When PRDX2 expression was diminished by spe-
ciﬁc siRNAs, OS cells acquired sensitivity to chemotherapeutic
drugs and showed a reduced potential for cell proliferation,
invasion, and migration [32]. We submitted a patent applica-
tion for the predictive utility of PRDX2 in OS and started a
nationwide multi-institutional validation study.
In this study, the use of open biopsy samples obtained
prior to chemotherapy was a critical factor. Because most OS
patients receive pre-operational neoadjuvant chemotherapy,
the affected surgically resected tissues become necrotic and
thus may not be adequate resources for the discovery of pre-
dictive OS biomarkers. On the contrary, open biopsy samples
routinely obtained from OS patients for pathological diag-
nosis present a valuable source of clinically relevant novel
biomarkers. However, the open biopsy samples are rarely
stored as frozen or formalin-ﬁxed and parafﬁn-embedded
(FFPE) tissues, limiting the availability of clinical specimens
for biomarker development. To compensate for this limita-
tion, we veriﬁed the functional signiﬁcance of PRDX2 protein
expression in vitro using OS cell lines. In general, the short-
age of clinical material is the main problem for the studies
of rare malignancies such as sarcoma, and the only work-
able approachmay be functional veriﬁcation and independent
validationperformedsystematically over a longperiodof time.6. Gastrointestinal stromal tumor
Gastrointestinal stromal tumor (GIST) is the most common
primary sarcoma of the gastrointestinal tract, representing
mics124 e u pa open proteo
1–3% of gastrointestinal tumors and affecting 15–20 in
1,000,000 people [71,72]. GIST cells originate from the inter-
stitial cells of Cajal, the pacemakers of peristaltic contraction
[73], and are characterized by unique genetic mutations in the
c-kit or PDGFRA genes [74–76]. The clinical course of GISTs
spans a wide spectrum ranging from a curable disorder to a
highly malignant disease. Treatment of GIST patients harbor-
ing c-kit or PDGFRA mutations, with tyrosine kinase inhibitors
such as imatinib and sunitinib, has been proven to be effec-
tive in cases of inoperable or metastatic tumors. As adjuvant
imatinib treatment signiﬁcantly improves recurrence-free sur-
vival [77], risk stratiﬁcation for imatinib therapy has become
an important step in the care of GIST patients. Three clinical
features of primary GISTs are used for risk assessment: size,
mitotic index, and location [74,78]; however, a subset of GIST
patients classiﬁed as low-risk occasionally has metastasis.
Therefore, in order to increase the speciﬁcity and sensitivity
of risk stratiﬁcation for imatinib treatment, it is necessary to
search for genetic abnormalities other than c-kit and PDGRFA
that are associated with GIST progression. These include
aberrant expression of ezrin [79], raf kinase inhibitor pro-
tein [80], COX-2 [81], Bcl-2, carbonic anhydrase II [82], cell
cycle/apoptosis regulators [83], and DNA methylation of spe-
ciﬁc tumor suppressor genes. GlobalmRNAexpression studies
conducted in GIST patients have identiﬁed various potential
biomarker candidates [84,85]; however, these genetic aber-
rations do not completely explain the mechanisms of GIST
aggressiveness, and no standard protocols based on these
genetic events have yet been established.
To identify metastasis-associated proteins and develop
prognostic biomarkers, we examined surgically resected
tumor tissues from 17 GIST patients with different post-
surgical outcomes: 8 patients had metastasis at diagnosis
or developed it within 1 year after surgery, and 9 did not
develop metastasis during 43–88 months of the observation
period. These populations were classiﬁed, respectively, as
high-risk and intermediate/low-risk groups based on patho-
logical observations; none of the patients received adjuvant
therapy. Using 2D-DIGE, we found 43 protein spots containing
25 unique proteins that showed signiﬁcant intensity differ-
ences between the two groups. Among these proteins, pfetin
detected in 8 protein spots was signiﬁcantly associated with
favorable outcome; this associationwas conﬁrmed bywestern
blotting and immunohistochemistry. In addition, quantitative
RT-PCR analysis also showed that the expression of pfetin
mRNA was signiﬁcantly different between the two patient
groups, although to a lesser degree than that of the protein
[36].
Pfetin was originally discovered the fetal cochlea [86], con-
sistent with the neuronal origin of GIST in the gut. Pfetin
has a potassium channel-like structure and is involved in the
GABA(B) receptor complex [87]. Although aberrant regulation
of potassium channels has been associated with the malig-
nant potential of tumor cells [88] and considered as candidate
treatment target, until our study, the association of pfetin
expressionwith favorable prognosis inGISTwasnever demon-
strated.
We then conﬁrmed our ﬁndings by immunohistochem-
istry, which is widely employed in clinical validation studies.4 ( 2 0 1 4 ) 121–128
Using an original polyclonal pfetin antibody [86], we were able
to conﬁrm the prognostic utility of pfetin in 210 GIST cases:
the 5-year disease-free survival rate of GIST patients with
pfetin-positive primary tumors was 93.9%, whereas that of
patients with pfetin-negative tumors was 36.2% (P<0.0001).
[36] We further validated the prognostic utility of pfetin in
additional 100 [38], 40 [89], and 72 [40] GIST cases at three hos-
pitals by immunohistochemistry usingmonoclonal antibodies
against recombinant pfetin developed in our laboratory. In
total, we examined the prognostic value of pfetin detection by
immunohistochemistry in 422 GIST cases. Our results clearly
demonstrated that pfetin was an independent prognostic fac-
tor, also applicable for risk classiﬁcation. When we stratiﬁed
GIST patients, we found that pfetin had prognostic value in
each risk classiﬁcation group. Later, Hasegawa et al. in a study
of 64 GIST patients in two hospitals obtained similar results
[43].
We discovered pfetin using 2D-DIGE in 2005, and reported
its prognostic utility after validation in 210 GIST cases in 2008
[36]. Over the next few years, we performed an additional vali-
dation study on 212 GIST cases [38,40,89] and collaborated
with other researchers in a study involving 64 patients [43].
In 2014, our original monoclonal antibody against pfetin was
commercialized (MBL, Japan) [44], and we are now planning a
nationwide clinical study of pfetin as a prognostic biomarker
in GIST. Our experience indicates that the discovery of a can-
cer protein biomarker could be accomplished in a relatively
short period, but clinical validation took considerably longer
time. It seems likely that a similar timetable would also apply
to biomarker studies in other malignancies, particularly rare
ones.
In addition to pfetin, 2D-DIGE-based proteomic analy-
sis resulted in the discovery of other promising proteins
associated with different post-operational outcomes for
GIST patients [39]. Among these proteins, ATP-dependent
RNA helicase DDX39 was conﬁrmed by immunohistochem-
istry to be signiﬁcantly associated with poor prognosis in
72 GIST cases [39]. As DDX39 and pfetin showed oppo-
site expression patterns, the combination of these two
GIST biomarkers potentially increases the probability of
correct diagnosis [40]. Recently, global expression studies
have identiﬁed ETV1 as a transcription factor unique to
GIST cells and have shown that ETV1 and the mutated c-
kit promoted tumor growth in a coordinated manner [90].
However, we found that ETV1 did not have prognostic
utility because there was no correlation between clinical
outcome and ETV1 expression in GIST patients [42], con-
ﬁrming the results of a previous study [91]. Gene silencing
experiments have demonstrated that KCTD10, a potassium
channel tetramerization domain (KCTD)-containing protein,
is regulated by ETV1, suggesting the association of KCTD10
expression with the malignant phenotype of GIST cells [90].
We tested this hypothesis by examining KCTD10 expres-
sion using immunohistochemistry, and found, contrary to
our expectations, that it was correlated with a favorable
GIST prognosis [42]. These data suggest that a number of
potential biomarker candidates with different prognostic util-
ity in GIST can be successfully identiﬁed by proteomics
approaches.
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. Perspectives
he rarity of sarcoma limits the number of clinical sam-
les available for biomarker development. There are several
pproaches to circumvent this problem. For example, FFPE
issues are suitable for long-term storage and have been
uccessfully used for proteomic analysis in cancer research.
owever, the number of FFPE sarcoma samples remains insuf-
cient to solve the problem. It is also difﬁcult to establish
ational or international collaborative efforts in order to share
aluable clinical material in the early discovery phase. More-
ver, as the pathological diagnosis of sarcomas is sometimes
ontroversial, and standard treatments are not always avail-
ble, the integration of samples and data from different
nstitutions may give rise to confusing results. At present,
here is no instant solution to the limited number of sarcoma
amples. However, the following approaches may be worth
onsidering in sarcoma biomarker studies.
Thorough functional veriﬁcation may be of help in
iomarker discovery. Genes that have a signiﬁcant associa-
ion with clinical observations are likely to be involved in the
iological mechanisms underlying poor prognosis and resis-
ance to treatment and may have prognostic value. Based on
his hypothesis, PRDX2 has been identiﬁed as a candidate pro-
nostic biomarker in OS; however, a functionally important
rotein ETV1has not consistently demonstrated its prognostic
tility [42]. As functionally relevant genes do not always have
linical value, mechanistic data indicate, but do not prove,
linical signiﬁcance of candidate biomarker genes prior to
alidation studies. There is another problem for functional
tudies conducted in vitro: cell lines are available for only
imited sarcoma histological types. Therefore, to facilitate
iomarker development by functional studies, novel type-
peciﬁc sarcoma cell lines should be established and shared
n the research community.
Consideration of molecular mechanisms involved in sar-
oma development may be another approach to compensate
or the limited number of clinical samples. For example, GISTs
ay have a relatively homogeneous molecular background,
wing to shared genetic alterations in the c-kit or PDGFRA
enes. Thus, we started our biomarker discovery program
sing only 17 GIST cases and identiﬁed pfetin, which was sub-
equently validated for prognostic utility in approximately 500
ases at six hospitals. The successful characterization and
linical application of pfetin may be attributable to a rela-
ively homogeneous molecular background underlying GIST
rogression. On the other hand, only a few GIST-related pro-
eins discovered using 2D-DIGE were successfully validated
y immunohistochemistry, suggesting that common mecha-
isms of carcinogenesis may not always warrant successful
iomarker discovery. The classiﬁcation of sarcomas based on
lobal gene expression proﬁling may contribute to the molec-
lar background-focusing approach, and mRNA and protein
lobal expression studies should be extended [28,29].
Focusing on technical characteristics of proteomics meth-
ds may be an effective strategy. Pfetin was detected in
protein spots showing higher intensity in patients with
avorable disease outcome. In 2D-DIGE, single gene prod-
cts can appear in multiple protein spots, probably as a( 2 0 1 4 ) 121–128 125
result of post-translational modiﬁcations, and the intensity
of such spots does not always correspond to protein expres-
sion level measured by SDS-PAGE/western blotting [34,92,93];
expression data obtained by mass spectrometry may have
the same problem. In such cases, the results of subsequent
immunohistochemical analysis may be discordant with those
of proteomics. For further immunohistochemical validation,
we may need to select proteins present in a single spot or
those detected in the protein spots showing similar intensities
within the same sample group; the latter may be consid-
ered as multiple biomarkers measurable by single antibodies.
However, in proteomics studies based on 2D-DIGE, only pro-
tein spots showing signiﬁcant intensity differences between
sample groups are subjected to protein identiﬁcation bymass-
spectrometry, and the number of protein spots containing
target proteins remains unknown. Accordingly, this strategy
is not always applicable for protein selection.
In conclusion, our experience suggests that a multi-
dimensional approach should be employed for the biomarker
development in rare cancers such as sarcomas. The strat-
egy based on reasonable sample stratiﬁcation according
to cancer biology and selection of promising proteins for
subsequent validation according to their functional signiﬁ-
cance together with appropriate proteomic techniques may
increase the chances of successful biomarker identiﬁcation.
Moreover, it is not possible for a single research group to
conduct all the studies required for identiﬁcation and vali-
dation of sarcoma biomarker candidates; inter-disciplinary
and multi-institutional collaborations are essential. Although
the strategy described in this article has been focused on sar-
comas, it can be generally applied to other rare malignancies.
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